{
  "$schema": "folio-library-document/v1",
  "id": "10665-357088",
  "title": "Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV",
  "variant": "pdf",
  "pages": 64,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Definition of key terms",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-definition-of-key-terms"
    },
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 8,
      "pageLabel": "vi",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-acknowledgements"
    },
    {
      "level": 1,
      "title": "Executive summary",
      "number": null,
      "page": 11,
      "pageLabel": "ix",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-executive-summary"
    },
    {
      "level": 1,
      "title": "Background",
      "number": "1",
      "page": 17,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-1-background"
    },
    {
      "level": 2,
      "title": "Objectives and target audience",
      "number": "1.1",
      "page": 17,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-11-objectives-and-target-audience"
    },
    {
      "level": 2,
      "title": "Guiding principles",
      "number": "1.2",
      "page": 18,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-12-guiding-principles"
    },
    {
      "level": 1,
      "title": "\u0007\u0007RECOMMENDATIONS ON DIAGNOSING AND PREVENTING CRYPTOCOCCAL DISEASE",
      "number": "2",
      "page": 19,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-2-recommendations-on-diagnosing-and-preventing-c"
    },
    {
      "level": 2,
      "title": "Diagnosing cryptococcal disease",
      "number": "2.1",
      "page": 19,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-21-diagnosing-cryptococcal-disease"
    },
    {
      "level": 3,
      "title": "Background",
      "number": "2.1.1",
      "page": 19,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-211-background"
    },
    {
      "level": 3,
      "title": "Rationale for the recommendations",
      "number": "2.1.2",
      "page": 20,
      "pageLabel": "4",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-212-rationale-for-the-recommendations"
    },
    {
      "level": 2,
      "title": "Preventing and screening for cryptococcal disease",
      "number": "2.2",
      "page": 20,
      "pageLabel": "4",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-22-preventing-and-screening-for-cryptococcal-dis"
    },
    {
      "level": 3,
      "title": "Background",
      "number": "2.2.1",
      "page": 20,
      "pageLabel": "4",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-221-background"
    },
    {
      "level": 3,
      "title": "Rationale for the recommendations",
      "number": "2.2.2",
      "page": 21,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-222-rationale-for-the-recommendations"
    },
    {
      "level": 3,
      "title": "Recommendations for children",
      "number": "2.2.3",
      "page": 22,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-223-recommendations-for-children"
    },
    {
      "level": 1,
      "title": "\u0007\u0007RECOMMENDATIONS ON INDUCTION, CONSOLIDATION AND MAINTENANCE ANTIFUNGAL TREATMENT REGIMENS",
      "number": "3",
      "page": 23,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-3-recommendations-on-induction-consolidation-and"
    },
    {
      "level": 2,
      "title": "Background",
      "number": "3.1",
      "page": 23,
      "pageLabel": "7",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-31-background"
    },
    {
      "level": 2,
      "title": "Induction therapy",
      "number": "3.2",
      "page": 24,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-32-induction-therapy"
    },
    {
      "level": 3,
      "title": "Rationale for the recommendations",
      "number": "3.2.1",
      "page": 24,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-321-rationale-for-the-recommendations"
    },
    {
      "level": 2,
      "title": "Preventing, monitoring and managing amphotericin B deoxycholate toxicity",
      "number": "3.3",
      "page": 27,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-33-preventing-monitoring-and-managing-amphoteric"
    },
    {
      "level": 2,
      "title": "Drug interactions",
      "number": "3.4",
      "page": 30,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-34-drug-interactions"
    },
    {
      "level": 2,
      "title": "Consolidation and maintenance treatment",
      "number": "3.5",
      "page": 30,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-35-consolidation-and-maintenance-treatment"
    },
    {
      "level": 3,
      "title": "Rationale for the recommendations",
      "number": "3.5.1",
      "page": 30,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-351-rationale-for-the-recommendations"
    },
    {
      "level": 2,
      "title": "Treatment for pregnant women",
      "number": "3.7",
      "page": 31,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-37-treatment-for-pregnant-women"
    },
    {
      "level": 2,
      "title": "Adjunctive corticosteroids in treating HIV-associated cryptococcal meningitis",
      "number": "3.8",
      "page": 31,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-38-adjunctive-corticosteroids-in-treating-hiv-as"
    },
    {
      "level": 2,
      "title": "Timing of ART initiation",
      "number": "3.9",
      "page": 32,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-39-timing-of-art-initiation"
    },
    {
      "level": 3,
      "title": "Rationale for the recommendation",
      "number": "3.9.1",
      "page": 32,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-391-rationale-for-the-recommendation"
    },
    {
      "level": 3,
      "title": "Implementation considerations",
      "number": "3.9.2",
      "page": 33,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-392-implementation-considerations"
    },
    {
      "level": 2,
      "title": "Monitoring and managing people with cryptococcal meningitis",
      "number": "3.10",
      "page": 33,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-310-monitoring-and-managing-people-with-cryptoco"
    },
    {
      "level": 3,
      "title": "Raised intracranial pressure",
      "number": "3.10.1",
      "page": 33,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-3101-raised-intracranial-pressure"
    },
    {
      "level": 3,
      "title": "Cryptococcal immune reconstitution inflammatory syndrome",
      "number": "3.10.2",
      "page": 35,
      "pageLabel": "19",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-3102-cryptococcal-immune-reconstitution-inflamma"
    },
    {
      "level": 1,
      "title": "\u0007\u0007IMPLEMENTATION CONSIDERATIONS",
      "number": "4",
      "page": 36,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-4-implementation-considerations"
    },
    {
      "level": 1,
      "title": "\u0007\u0007RESEARCH NEEDS",
      "number": "5",
      "page": 38,
      "pageLabel": "22",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-5-research-needs"
    },
    {
      "level": 1,
      "title": "UPDATING AND DISSEMINATION",
      "number": "6",
      "page": 39,
      "pageLabel": "23",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-6-updating-and-dissemination"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 40,
      "pageLabel": "24",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-033-references"
    },
    {
      "level": 1,
      "title": "ANNEX 1. Process for developing the guidelines",
      "number": null,
      "page": 45,
      "pageLabel": "29",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-034-annex-1-process-for-developing-the-guidelines"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 48,
      "pageLabel": "32",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-035-references"
    },
    {
      "level": 1,
      "title": "Web Annex 1. Declarations of interest for the Guideline Development Group and External Peer Review Group",
      "number": null,
      "page": 49,
      "pageLabel": "33",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-036-web-annex-1-declarations-of-interest-for-the-gui"
    },
    {
      "level": 1,
      "title": "Web Annex 2. Systematic review and GRADE evidence profile on treatment strategies for HIV-associated cryptococcal meningitis",
      "number": null,
      "page": 53,
      "pageLabel": "37",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": null
    },
    {
      "level": 2,
      "title": "Abstract",
      "number": null,
      "page": 53,
      "pageLabel": "37",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-037-abstract"
    },
    {
      "level": 2,
      "title": "Background",
      "number": null,
      "page": 54,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-038-background"
    },
    {
      "level": 2,
      "title": "Methods",
      "number": null,
      "page": 54,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-039-methods"
    },
    {
      "level": 2,
      "title": "Results",
      "number": null,
      "page": 56,
      "pageLabel": "40",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-040-results"
    },
    {
      "level": 2,
      "title": "Discussion",
      "number": null,
      "page": 57,
      "pageLabel": "41",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-041-discussion"
    },
    {
      "level": 2,
      "title": "Acknowledgements",
      "number": null,
      "page": 57,
      "pageLabel": "41",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-042-acknowledgements"
    },
    {
      "level": 2,
      "title": "Fig. A1. Study selection",
      "number": null,
      "page": 57,
      "pageLabel": "41",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-043-fig-a1-study-selection"
    },
    {
      "level": 2,
      "title": "Supplemental Fig. 1. Risk of bias summary",
      "number": null,
      "page": 58,
      "pageLabel": "42",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-044-supplemental-fig-1-risk-of-bias-summary"
    },
    {
      "level": 2,
      "title": "Appendix. Search strategy: utility and impact review",
      "number": null,
      "page": 58,
      "pageLabel": "42",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-045-appendix-search-strategy-utility-and-impact-revi"
    },
    {
      "level": 2,
      "title": "GRADE evidence profile on updated systematic review of HIV-associated cryptococcal meningitis treatment strategies",
      "number": null,
      "page": 59,
      "pageLabel": "43",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-046-grade-evidence-profile-on-updated-systematic-rev"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 60,
      "pageLabel": "44",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-047-references"
    },
    {
      "level": 1,
      "title": "Web Annex 3. Evidence-to-decision-making table",
      "number": null,
      "page": 61,
      "pageLabel": "45",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-048-web-annex-3-evidence-to-decision-making-table"
    },
    {
      "level": 2,
      "title": "Summary of judgements",
      "number": null,
      "page": 61,
      "pageLabel": "45",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-049-summary-of-judgements"
    },
    {
      "level": 2,
      "title": "Detailed evidence-to-decision-making table",
      "number": null,
      "page": 61,
      "pageLabel": "45",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-050-detailed-evidence-to-decision-making-table"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 7,
      "labelStart": "A",
      "labelEnd": "v",
      "words": 838,
      "summary": {
        "text": "The cover, copyright page and table of contents of WHO's 2022 guidelines on diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV, including annexes on methods, evidence profiles and evidence-to-decision tables.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "managing cryptococcal",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "hiv-associated cryptococcal",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "mediation rules",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "evidence-to-decision-making table",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        }
      ],
      "extract": "GUIDELINES FOR DIAGNOSING, PREVENTING AND MANAGING CRYPTOCOCCAL DISEASE AMONG ADULTS, ADOLESCENTS AND CHILDREN LIVING WITH HIV GUIDELINES FOR DIAGNOSING, PREVENTING AND MANAGING CRYPTOCOCCAL DISEASE AMONG ADULTS, ADOLESCENTS AND CHILDREN LIVING WITH HIV Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV ISBN 978-92-4-005217-8 (electronic",
      "extractCut": true,
      "blocks": [
        "library/10665-357088/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-definition-of-key-terms",
      "number": null,
      "title": "Definition of key terms",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 8,
      "labelStart": "v",
      "labelEnd": "vi",
      "words": 466,
      "summary": {
        "text": "Defines the age groups used in the cryptococcal disease guidelines and terms such as advanced HIV disease, cryptococcal antigen positivity, cryptococcal infection and disease, relapse, sustained clinical response and treatment failure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcus species",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "clinical symptoms",
          "heading": false
        },
        {
          "term": "hiv disease",
          "heading": false
        },
        {
          "term": "antigen test",
          "heading": false
        }
      ],
      "extract": "Age groups The following definitions for adults, adolescents, children and infants are used in these guidelines for the purpose of implementing recommendations for specific age groups. Countries may have other definitions under national laws. • An adult is a person older than 19 years of age. • An adolescent is a person 10–19 years of age inclusive. • A child is a person one year to younger than 10 years of age. •",
      "extractCut": true
    },
    {
      "id": "sec-001-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 11,
      "labelStart": "vi",
      "labelEnd": "ix",
      "words": 1058,
      "summary": {
        "text": "Thanks the individuals and organizations who contributed to updating the cryptococcal disease guidelines, listing the Guideline Development Group, reviewers, WHO staff and regional offices. It notes that Unitaid funded the work.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "university nijmegen",
          "heading": false
        },
        {
          "term": "radboud university",
          "heading": false
        },
        {
          "term": "university college",
          "heading": false
        },
        {
          "term": "george university",
          "heading": false
        },
        {
          "term": "columbia university",
          "heading": false
        },
        {
          "term": "university clinical",
          "heading": false
        },
        {
          "term": "college london",
          "heading": false
        },
        {
          "term": "united kingdom",
          "heading": false
        }
      ],
      "extract": "WHO gratefully acknowledges the contributions of many individuals and organizations to update these guidelines. Guideline Development Group Co-Chairs: Alexandra Calmy (Hôpitaux Universitaires de Genève, Switzerland) and Nelesh Govender (National Institute for Communicable Diseases and University of the Witwatersrand, South Africa). Eduardo Arathoon (Hospital General San Juan de Dios, Guatemala), Mohamed Chakroun",
      "extractCut": true
    },
    {
      "id": "sec-002-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 17,
      "labelStart": "ix",
      "labelEnd": "1",
      "words": 2160,
      "summary": {
        "text": "Summarizes the burden of cryptococcal disease in advanced HIV, noting an estimated 181,100 deaths from cryptococcal meningitis in 2014, and explains that these guidelines replace the 2018 edition. It presents the main recommendations on diagnosis, antigen screening, preventive fluconazole and the new preferred induction regimen based on 2021 evidence. The summary also covers consolidation and maintenance treatment, deferred ART, managing raised intracranial pressure and steps for handling relapse.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lumbar puncture",
          "heading": false
        },
        {
          "term": "csf cryptococcal",
          "heading": false
        },
        {
          "term": "intracranial pressure",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "opening pressure",
          "heading": false
        },
        {
          "term": "managing cryptococcal",
          "heading": false
        },
        {
          "term": "raised intracranial",
          "heading": false
        }
      ],
      "extract": "Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to illness, disability and mortality (1). By far the most common presentation is cryptococcal meningitis, which caused an estimated 223 100 incident cases and 181 100 deaths among people living with HIV in 2014 and accounted for 15% of all the people dying from HIV-related",
      "extractCut": true
    },
    {
      "id": "sec-003-1-background",
      "number": "1",
      "title": "Background",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 327,
      "summary": {
        "text": "Gives the background to cryptococcal disease as an opportunistic infection in advanced HIV, its high mortality especially in low-income countries, and the 2021 trial that prompted the update. It notes that the disease is uncommon in children and mostly presents as meningitis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "among people",
          "heading": false
        },
        {
          "term": "low-income countries",
          "heading": false
        },
        {
          "term": "contributor",
          "heading": false
        },
        {
          "term": "mortality",
          "heading": false
        },
        {
          "term": "hiv-related",
          "heading": false
        }
      ],
      "extract": "Cryptococcal disease is one of the most important opportunistic infections among people living with advanced HIV disease and is a major contributor to illness, disability and mortality (1–5). Clinically significant invasive disease is primarily caused by reactivation of latent infection among immunocompromised individuals, such as people living with HIV, months to years after initial exposure (6). By far the most",
      "extractCut": true
    },
    {
      "id": "sec-004-11-objectives-and-target-audience",
      "number": "1.1",
      "title": "Objectives and target audience",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 60,
      "summary": {
        "text": "States that the guidelines aim to give updated recommendations on treating cryptococcal disease in people with HIV and are intended for programme managers, policy-makers, clinicians and people living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "evidence-informed",
          "heading": false
        }
      ],
      "extract": "The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policy-makers, national treatment health care professionals and people living with HIV. 2 Guidelines for diagnosing, preventing and managing cryptococcal disease among adults,",
      "extractCut": true
    },
    {
      "id": "sec-005-12-guiding-principles",
      "number": "1.2",
      "title": "Guiding principles",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 243,
      "summary": {
        "text": "Lists the guiding principles behind the guidelines, such as rapid ART initiation, early diagnosis and antifungal treatment, and deferring ART after a positive antigen screen or confirmed meningitis. It adds that implementation should reflect local epidemiology and context.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "among people",
          "heading": false
        },
        {
          "term": "deferred",
          "heading": false
        },
        {
          "term": "prompt",
          "heading": false
        }
      ],
      "extract": "The following principles have informed the development of these guidelines and should guide the implementation of the recommendations. • The guidelines are based on a public health approach to scaling up the use of antiretroviral drugs along the continuum of HIV prevention, care and treatment. • Rapid ART initiation regardless of CD4 cell count or immune status is the most important preventive strategy to reduce the",
      "extractCut": true
    },
    {
      "id": "sec-006-21-diagnosing-cryptococcal-disease",
      "number": "2.1",
      "title": "Diagnosing cryptococcal disease",
      "level": 2,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 11,
      "summary": {
        "text": "Notes that WHO's 2018 recommendations on diagnosing cryptococcal disease remain unchanged.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "The 2018 WHO recommendations for diagnosing cryptococcal disease remain unchanged (16).",
      "extractCut": false
    },
    {
      "id": "sec-007-211-background",
      "number": "2.1.1",
      "title": "Background",
      "level": 3,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 467,
      "summary": {
        "text": "Stresses early diagnosis of cryptococcal meningitis and sets out the 2018 recommendation for prompt lumbar puncture with opening pressure measurement and rapid antigen testing. It describes diagnostic approaches according to access to lumbar puncture and rapid tests and lists contraindications to lumbar puncture.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "lumbar puncture",
          "heading": false
        },
        {
          "term": "csf cryptococcal",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "suspecting cryptococcal",
          "heading": false
        },
        {
          "term": "antigen assay",
          "heading": false
        },
        {
          "term": "low-certainty evidence",
          "heading": false
        },
        {
          "term": "moderate-certainty evidence",
          "heading": false
        }
      ],
      "extract": "Early diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from cryptococcal disease. Health-care professionals should have a low threshold for suspecting cryptococcal meningitis among people with advanced HIV disease. National programmes should give priority to reliable access to rapid diagnostic cryptococcal antigen assays, preferably lateral flow assays, for use in cerebrospinal fluid",
      "extractCut": true
    },
    {
      "id": "sec-008-2-recommendations-on-diagnosing-and-preventing-c",
      "number": "2",
      "title": "\u0007\u0007RECOMMENDATIONS ON DIAGNOSING AND PREVENTING CRYPTOCOCCAL DISEASE",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 80,
      "summary": {
        "text": "A summary chart of the diagnostic approach to cryptococcal meningitis, depending on whether lumbar puncture and rapid antigen tests are available.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal disease",
          "heading": true
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "rapid cryptococcal",
          "heading": false
        },
        {
          "term": "lumbar puncture",
          "heading": false
        }
      ],
      "extract": "PREVENTING CRYPTOCOCCAL DISEASE 4 Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV Summary of the diagnostic approach to cryptococcal meningitis Lumbar puncture available Lumbar puncture not available or contraindicated Rapid cryptococcal antigen test available CSF cryptococcal antigen (preferably lateral flow assay) Serum, plasma or",
      "extractCut": true
    },
    {
      "id": "sec-009-212-rationale-for-the-recommendations",
      "number": "2.1.2",
      "title": "Rationale for the recommendations",
      "level": 3,
      "pageStart": 20,
      "pageEnd": 20,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 225,
      "summary": {
        "text": "Explains that rapid cryptococcal antigen assays are preferred over India ink because they are more accurate and need less skill, and why lateral-flow assays are favoured. It notes that blood antigen testing does not replace lumbar puncture where feasible and that the adult recommendations are extended to children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lumbar puncture",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "whole-blood cryptococcal",
          "heading": false
        },
        {
          "term": "rapid cryptococcal",
          "heading": false
        },
        {
          "term": "plasma",
          "heading": false
        },
        {
          "term": "serum",
          "heading": false
        },
        {
          "term": "laboratory infrastructure",
          "heading": false
        },
        {
          "term": "csf",
          "heading": false
        }
      ],
      "extract": "Rapid cryptococcal antigen assay in CSF, serum, plasma or whole blood (depending on access to lumbar puncture) is preferred based on the much higher diagnostic accuracy of these rapid cryptococcal antigen assays versus the India ink test and the fact that these rapid assays depend less on the health-care provider’s skills. Advantages of the lateral-flow assay over the latex agglutination assay include its rapid (<10",
      "extractCut": true
    },
    {
      "id": "sec-010-22-preventing-and-screening-for-cryptococcal-dis",
      "number": "2.2",
      "title": "Preventing and screening for cryptococcal disease",
      "level": 2,
      "pageStart": 20,
      "pageEnd": 20,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 14,
      "summary": {
        "text": "Notes that WHO's 2018 recommendations on preventing and screening for cryptococcal disease remain unchanged.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "The 2018 WHO recommendations for prevention and screening for cryptococcal disease remain unchanged (16).",
      "extractCut": false
    },
    {
      "id": "sec-011-221-background",
      "number": "2.2.1",
      "title": "Background",
      "level": 3,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "4",
      "labelEnd": "5",
      "words": 358,
      "summary": {
        "text": "Explains that early ART is the main way to prevent cryptococcal disease and sets out the 2018 recommendations on antigen screening before ART, pre-emptive antifungal therapy and fluconazole prophylaxis where screening is unavailable. It stresses evaluating everyone who screens positive for meningitis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "csf cryptococcal",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "antigen screening",
          "heading": false
        },
        {
          "term": "antigen assay",
          "heading": false
        },
        {
          "term": "india ink",
          "heading": false
        },
        {
          "term": "csf examination",
          "heading": false
        },
        {
          "term": "count cells",
          "heading": false
        }
      ],
      "extract": "Early diagnosis and initiation of antiretroviral therapy remains the most important preventive strategy to reduce the incidence of cryptococcal disease among people living with HIV and the associated high mortality.2 Screening for cryptococcal antigenaemia is the optimal approach for guiding resources in a public health approach and is the preferred approach for identifying infection when managing people aged 10",
      "extractCut": true
    },
    {
      "id": "sec-012-222-rationale-for-the-recommendations",
      "number": "2.2.2",
      "title": "Rationale for the recommendations",
      "level": 3,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 516,
      "summary": {
        "text": "Gives the rationale for screening adults and adolescents with low CD4 counts for cryptococcal antigen before ART and for pre-emptive fluconazole in those who test positive. It covers evaluating antigen-positive people for meningitis and when to stop primary fluconazole prophylaxis, citing trials.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "whole-blood cryptococcal",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "antigen screening",
          "heading": false
        },
        {
          "term": "lumbar puncture",
          "heading": false
        },
        {
          "term": "fluconazole primary",
          "heading": false
        },
        {
          "term": "antigen assay",
          "heading": false
        }
      ],
      "extract": "Since 2018, WHO guidelines have recommended that all adults and adolescents living with HIV who have a CD4 cell count <100 cells/mm3 be screened for cryptococcal antigen before ART initiation or reinitiation; cryptococcal antigen screening may also be considered for adults and adolescents living with HIV who have a CD4 cell count <200 cells/mm3. These recommendations were supported by evidence favouring the clinical",
      "extractCut": true
    },
    {
      "id": "sec-013-223-recommendations-for-children",
      "number": "2.2.3",
      "title": "Recommendations for children",
      "level": 3,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 59,
      "summary": {
        "text": "Explains that the screening and prophylaxis recommendations are not extended to children because the disease is rare in them, and introduces the new 2022 induction recommendation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "recommendations",
          "heading": true
        },
        {
          "term": "children",
          "heading": true
        },
        {
          "term": "antifungal",
          "heading": false
        }
      ],
      "extract": "These recommendations apply to adults and adolescents with advanced HIV disease. The decision not to extend these recommendations to children was based on the recognition that cryptococcal disease in this age group is rare, even in countries with high incidence (4,10). These 2022 guidelines provide a new recommendation for the preferred antifungal regimen for the induction phase of treatment.",
      "extractCut": false
    },
    {
      "id": "sec-014-31-background",
      "number": "3.1",
      "title": "Background",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 371,
      "summary": {
        "text": "Describes the 2018 induction regimens for cryptococcal meningitis based on amphotericin B and flucytosine, along with alternatives when drugs are unavailable, and the extrapolation of evidence to children. It notes that fluconazole monotherapy is not recommended and that WHO met in 2022 to consider a single high-dose liposomal amphotericin B regimen.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "amphotericin deoxycholate",
          "heading": false
        },
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "high-dose liposomal",
          "heading": false
        },
        {
          "term": "amphotericin based",
          "heading": false
        },
        {
          "term": "single high-dose",
          "heading": false
        },
        {
          "term": "seven days",
          "heading": false
        },
        {
          "term": "based regimen",
          "heading": false
        },
        {
          "term": "flucytosine",
          "heading": false
        }
      ],
      "extract": "The 2018 WHO guidelines recommended seven days of amphotericin B deoxycholate and flucytosine-based therapy (followed by seven days of fluconazole 1200 mg) as the preferred antifungal regimen for the induction phase of treatment of HIV-associated cryptococcal meningitis. This was a strong recommendation based on moderate-certainty evidence for adults and low-certainty evidence for children and adolescents (3).",
      "extractCut": true
    },
    {
      "id": "sec-015-3-recommendations-on-induction-consolidation-and",
      "number": "3",
      "title": "\u0007\u0007RECOMMENDATIONS ON INDUCTION, CONSOLIDATION AND MAINTENANCE ANTIFUNGAL TREATMENT REGIMENS",
      "level": 1,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 23,
      "summary": {
        "text": "A section heading for the recommendations on induction, consolidation and maintenance antifungal treatment regimens.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "CONSOLIDATION AND MAINTENANCE ANTIFUNGAL TREATMENT REGIMENS 8 Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV",
      "extractCut": false
    },
    {
      "id": "sec-016-32-induction-therapy",
      "number": "3.2",
      "title": "Induction therapy",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 315,
      "summary": {
        "text": "Sets out the 2022 recommendation of a single high dose of liposomal amphotericin B with 14 days of flucytosine and fluconazole as preferred induction therapy for cryptococcal meningitis. It lists alternative regimens for when liposomal amphotericin B, any amphotericin or flucytosine is unavailable and stresses the value of flucytosine.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "amphotericin deoxycholate",
          "heading": false
        },
        {
          "term": "moderate-certainty evidence",
          "heading": false
        },
        {
          "term": "induction",
          "heading": true
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "low-certainty evidence",
          "heading": false
        },
        {
          "term": "fluconazole",
          "heading": false
        },
        {
          "term": "flucytosine",
          "heading": false
        }
      ],
      "extract": "Induction therapy (2022 recommendations) A single high dose (10 mg/kg) of liposomal amphotericin B with 14 days of flucytosine (100 mg/kg per day divided into four doses per day) and fluconazole (1200 mg/daily for adults; 12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily) should be used as the preferred induction regimen for treating people with cryptococcal meningitis. Strong",
      "extractCut": true
    },
    {
      "id": "sec-017-321-rationale-for-the-recommendations",
      "number": "3.2.1",
      "title": "Rationale for the recommendations",
      "level": 3,
      "pageStart": 24,
      "pageEnd": 27,
      "labelStart": "8",
      "labelEnd": "11",
      "words": 1419,
      "summary": {
        "text": "Reviews the randomized trial in five African countries that compared single high-dose liposomal amphotericin B with the 2018 standard regimen in 844 people with cryptococcal meningitis. It reports that 10-week mortality was 24.8% versus 28.7%, showing non-inferiority, with fewer serious adverse events such as anaemia and kidney toxicity. The section also weighs costs, feasibility, acceptability and equity, noting the reduced burden on health workers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "amphotericin deoxycholate",
          "heading": false
        },
        {
          "term": "high-dose liposomal",
          "heading": false
        },
        {
          "term": "single-dose liposomal",
          "heading": false
        },
        {
          "term": "amphotericin group",
          "heading": false
        },
        {
          "term": "amphotericin containing",
          "heading": false
        },
        {
          "term": "single high-dose",
          "heading": false
        },
        {
          "term": "fewer intravenous",
          "heading": false
        }
      ],
      "extract": "A systematic review from 2022 identified one randomized trial comparing a single high dose of liposomal amphotericin B, combined with oral flucytosine and fluconazole for 14 days, compared with the preferred induction therapy recommended by WHO in 2018 (38). The trial, conducted in Botswana, Malawi, South Africa, Uganda and Zimbabwe, enrolled 844 individuals with HIV-associated cryptococcal meningitis who were",
      "extractCut": true
    },
    {
      "id": "sec-018-33-preventing-monitoring-and-managing-amphoteric",
      "number": "3.3",
      "title": "Preventing, monitoring and managing amphotericin B deoxycholate toxicity",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 30,
      "labelStart": "11",
      "labelEnd": "14",
      "words": 971,
      "summary": {
        "text": "Sets out good practice principles for preventing, monitoring and managing amphotericin B toxicity, such as hypokalaemia, nephrotoxicity and anaemia. It describes pre-hydration, electrolyte supplementation and laboratory monitoring, and how to weigh continuing deoxycholate treatment when severe anaemia develops.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "amphotericin deoxycholate",
          "heading": true
        },
        {
          "term": "managing toxicity",
          "heading": true
        },
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "serum potassium",
          "heading": false
        },
        {
          "term": "serum creatinine",
          "heading": false
        },
        {
          "term": "amphotericin related",
          "heading": false
        },
        {
          "term": "magnesium supplementation",
          "heading": false
        },
        {
          "term": "deoxycholate regimen",
          "heading": false
        }
      ],
      "extract": "deoxycholate toxicity Managing toxicity (2022 good practice principles) Infusion-related toxicity and side-effects from amphotericin B therapy are barriers to optimal induction treatment, especially in low- and middle-income countries. • Safe administration of amphotericin B should be given priority and may require referral to a centre with access to the recommended package of preventing, monitoring and managing",
      "extractCut": true
    },
    {
      "id": "sec-019-34-drug-interactions",
      "number": "3.4",
      "title": "Drug interactions",
      "level": 2,
      "pageStart": 30,
      "pageEnd": 30,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 143,
      "summary": {
        "text": "Describes possible interactions between antifungal drugs and ART, advising kidney monitoring and dose adjustment of tenofovir with amphotericin and haematological monitoring with flucytosine.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "receiving amphotericin",
          "heading": false
        },
        {
          "term": "renal function",
          "heading": false
        },
        {
          "term": "tdf",
          "heading": false
        },
        {
          "term": "preparations",
          "heading": false
        },
        {
          "term": "flucytosine",
          "heading": false
        }
      ],
      "extract": "Drug interactions in the context of concurrent use of amphotericin, flucytosine and fluconazole alongside ART regimens have not been well documented (45). However, individuals receiving tenofovir disoproxil fumarate (TDF)–based regimens who are receiving amphotericin or recently received amphotericin B preparations should be closely monitored for nephrotoxicity. Liposomal preparations of amphotericin B are",
      "extractCut": true
    },
    {
      "id": "sec-020-35-consolidation-and-maintenance-treatment",
      "number": "3.5",
      "title": "Consolidation and maintenance treatment",
      "level": 2,
      "pageStart": 30,
      "pageEnd": 30,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 98,
      "summary": {
        "text": "Restates the unchanged 2018 recommendations for fluconazole doses in the consolidation phase and in maintenance therapy until immune reconstitution.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "consolidation",
          "heading": true
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "maintenance",
          "heading": true
        }
      ],
      "extract": "The 2018 WHO recommendations for consolidation and maintenance treatment for cryptococcal disease remain unchanged (16). Consolidation (2018 recommendation) Recommendation Fluconazole (800 mg daily for adults, 6–12 mg/kg per day for children and adolescents up to a maximum of 800 mg daily) is recommended for the consolidation phase (for eight weeks following the induction phase). Strong recommendation; low-certainty",
      "extractCut": true
    },
    {
      "id": "sec-021-351-rationale-for-the-recommendations",
      "number": "3.5.1",
      "title": "Rationale for the recommendations",
      "level": 3,
      "pageStart": 30,
      "pageEnd": 31,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 353,
      "summary": {
        "text": "Explains the evidence behind fluconazole consolidation and maintenance doses and its role in preventing relapse. It also suggests expert-opinion regimens for localized non-meningeal disease, cryptococcomas and disseminated disease.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "cerebral parenchymal",
          "heading": false
        },
        {
          "term": "localized non-meningeal",
          "heading": false
        },
        {
          "term": "disseminated cryptococcal",
          "heading": false
        },
        {
          "term": "lumbar puncture",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "eight weeks",
          "heading": false
        },
        {
          "term": "weeks followed",
          "heading": false
        }
      ],
      "extract": "WHO recommends fluconazole at 800 mg/day for eight weeks following an amphotericin B deoxycholate–based induction regimen; these recommendations were based primarily on expert opinion, considering the limited evidence from two trials that compared itraconazole versus fluconazole at lower doses (48,49). Recent guidelines from the European AIDS Clinical Society recommend 400 mg for eight weeks after a single loading",
      "extractCut": true
    },
    {
      "id": "sec-022-37-treatment-for-pregnant-women",
      "number": "3.7",
      "title": "Treatment for pregnant women",
      "level": 2,
      "pageStart": 31,
      "pageEnd": 31,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 104,
      "summary": {
        "text": "Advises that amphotericin B may be given in pregnancy when benefits outweigh harm, while flucytosine and fluconazole use should be judged case by case because of possible birth defects.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pregnant women",
          "heading": true
        },
        {
          "term": "amphotericin",
          "heading": false
        },
        {
          "term": "flucytosine",
          "heading": false
        },
        {
          "term": "fluconazole",
          "heading": false
        }
      ],
      "extract": "Amphotericin B therapy can be given to pregnant women with meningeal and non-meningeal disease when the benefits outweigh the harm. Liposomal amphotericin B is considered as a pregnancy category B drug and although animal reproduction studies have failed to demonstrate a risk, an increase in spontaneous abortions was noted at higher doses. Exposure to flucytosine and fluconazole during pregnancy has been associated",
      "extractCut": true
    },
    {
      "id": "sec-023-38-adjunctive-corticosteroids-in-treating-hiv-as",
      "number": "3.8",
      "title": "Adjunctive corticosteroids in treating HIV-associated cryptococcal meningitis",
      "level": 2,
      "pageStart": 31,
      "pageEnd": 32,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 218,
      "summary": {
        "text": "Restates the 2018 recommendation against routine adjunctive corticosteroids during induction treatment of cryptococcal meningitis, citing trial evidence of more disability and adverse events. It notes that a paediatric advisory group found no reason for a different approach in children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": true
        },
        {
          "term": "hiv-associated cryptococcal",
          "heading": true
        },
        {
          "term": "adjunctive",
          "heading": true
        },
        {
          "term": "corticosteroids",
          "heading": true
        },
        {
          "term": "adjuvant corticosteroids",
          "heading": false
        },
        {
          "term": "induction phase",
          "heading": false
        },
        {
          "term": "corticosteroid therapy",
          "heading": false
        }
      ],
      "extract": "cryptococcal meningitis Adjunctive corticosteroids (2018 recommendation) Routine use of adjunctive corticosteroid therapy during the induction phase is not recommended in treating adults, adolescents and children who have HIV-associated cryptococcal meningitis. Strong recommendation; high-certainty evidence for adults and adolescents and moderate-certainty evidence for children 16 Guidelines for diagnosing,",
      "extractCut": true
    },
    {
      "id": "sec-024-39-timing-of-art-initiation",
      "number": "3.9",
      "title": "Timing of ART initiation",
      "level": 2,
      "pageStart": 32,
      "pageEnd": 32,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 55,
      "summary": {
        "text": "Restates the 2018 recommendation that ART be deferred 4–6 weeks after starting antifungal treatment for cryptococcal meningitis because immediate ART raises mortality.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art",
          "heading": true
        },
        {
          "term": "initiation",
          "heading": true
        },
        {
          "term": "timing",
          "heading": true
        }
      ],
      "extract": "Timing of ART (2018 recommendations) Immediate ART initiation is not recommended among adults, adolescents and children living with HIV who have cryptococcal meningitis because of the risk of increased mortality and should be deferred 4–6 weeks from the initiation of antifungal treatment. Strong recommendation; low-certainty evidence for adults and very-low-certainty evidence for children and adolescents",
      "extractCut": false
    },
    {
      "id": "sec-025-391-rationale-for-the-recommendation",
      "number": "3.9.1",
      "title": "Rationale for the recommendation",
      "level": 3,
      "pageStart": 32,
      "pageEnd": 33,
      "labelStart": "16",
      "labelEnd": "17",
      "words": 229,
      "summary": {
        "text": "Explains the evidence from four trials that early ART after cryptococcal meningitis increases mortality and specifies deferral periods depending on the induction regimen. It also discusses the limited evidence on ART timing for people who are antigen-positive without meningitis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "lumbar puncture",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "start art",
          "heading": false
        },
        {
          "term": "induction regimen",
          "heading": false
        },
        {
          "term": "weeks following",
          "heading": false
        },
        {
          "term": "amphotericin",
          "heading": false
        }
      ],
      "extract": "The optimal timing of ART after cryptococcal meningitis was informed by a systematic review that identified four randomized controlled trials (62). Overall, early ART initiation increased mortality compared with delaying ART initiation (pooled relative risk for mortality at 6–12 months, 1.42, 95% CI 1.02–1.97). Immediately initiating ART is therefore not recommended among people with cryptococcal meningitis because",
      "extractCut": true
    },
    {
      "id": "sec-026-392-implementation-considerations",
      "number": "3.9.2",
      "title": "Implementation considerations",
      "level": 3,
      "pageStart": 33,
      "pageEnd": 33,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 44,
      "summary": {
        "text": "Advises evaluating people already on ART who develop cryptococcal meningitis for treatment failure and deferring any ART switch by four to six weeks.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "induction regimen",
          "heading": false
        },
        {
          "term": "weeks following",
          "heading": false
        },
        {
          "term": "art-experienced",
          "heading": false
        }
      ],
      "extract": "ART-experienced people who develop cryptococcal meningitis should be evaluated for potential underlying ART treatment failure, ideally through confirmation by HIV viral load. ART switches should be deferred by four weeks following an amphotericin B–based induction regimen or 4–6 weeks following a fluconazole-based induction regimen.",
      "extractCut": false
    },
    {
      "id": "sec-027-310-monitoring-and-managing-people-with-cryptoco",
      "number": "3.10",
      "title": "Monitoring and managing people with cryptococcal meningitis",
      "level": 2,
      "pageStart": 33,
      "pageEnd": 33,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-028-3101-raised-intracranial-pressure",
      "number": "3.10.1",
      "title": "Raised intracranial pressure",
      "level": 3,
      "pageStart": 33,
      "pageEnd": 35,
      "labelStart": "17",
      "labelEnd": "19",
      "words": 732,
      "summary": {
        "text": "Explains that raised intracranial pressure affects up to 80% of people with HIV-associated cryptococcal meningitis and that lowering it improves survival. It recommends an initial and early repeat lumbar puncture with pressure measurement regardless of symptoms, with therapeutic drainage when pressure is high. Practical notes cover settings without manometers and the volume of fluid that can be removed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "intracranial pressure",
          "heading": true
        },
        {
          "term": "raised intracranial",
          "heading": true
        },
        {
          "term": "lumbar puncture",
          "heading": false
        },
        {
          "term": "csf pressure",
          "heading": false
        },
        {
          "term": "therapeutic lumbar",
          "heading": false
        },
        {
          "term": "opening pressure",
          "heading": false
        },
        {
          "term": "repeat lumbar",
          "heading": false
        },
        {
          "term": "csf drainage",
          "heading": false
        }
      ],
      "extract": "Initial measurement of intracranial pressure and management of raised intracranial pressure are an essential part of cryptococcal meningitis management to prevent death and serious nervous system complications. Raised intracranial pressure is a frequent and potentially life-threatening complication, occurring in up to 80% of people with HIV-associated cryptococcal meningitis. The limitations of using clinical",
      "extractCut": true
    },
    {
      "id": "sec-029-3102-cryptococcal-immune-reconstitution-inflamma",
      "number": "3.10.2",
      "title": "Cryptococcal immune reconstitution inflammatory syndrome",
      "level": 3,
      "pageStart": 35,
      "pageEnd": 36,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 207,
      "summary": {
        "text": "Describes cryptococcal immune reconstitution inflammatory syndrome after starting ART and lists management steps: continue ART, control intracranial pressure, optimize antifungals and consider short-course steroids for life-threatening deterioration.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "reconstitution inflammatory",
          "heading": true
        },
        {
          "term": "inflammatory syndrome",
          "heading": true
        },
        {
          "term": "immune reconstitution",
          "heading": true
        },
        {
          "term": "cryptococcal immune",
          "heading": true
        },
        {
          "term": "intracranial pressure",
          "heading": false
        },
        {
          "term": "raised intracranial",
          "heading": false
        },
        {
          "term": "antifungal therapy",
          "heading": false
        }
      ],
      "extract": "Paradoxical cryptococcal immune reconstitution inflammatory syndrome is associated with high mortality (13). The median time to onset in reported cohort studies is typically 3–12 weeks after initiating ART (67). Raised intracranial pressure is a common feature of cryptococcal immune reconstitution inflammatory syndrome and an important contributor to high mortality (68). Multiple repeat lumbar puncture may be",
      "extractCut": true
    },
    {
      "id": "sec-030-4-implementation-considerations",
      "number": "4",
      "title": "\u0007\u0007IMPLEMENTATION CONSIDERATIONS",
      "level": 1,
      "pageStart": 36,
      "pageEnd": 38,
      "labelStart": "20",
      "labelEnd": "22",
      "words": 724,
      "summary": {
        "text": "Discusses practical issues in implementing the guidelines, including access to rapid antigen assays, laboratory reflex screening and task sharing. It also covers access to essential antifungal medicines, especially flucytosine and liposomal amphotericin B, and adapting the toxicity monitoring package to available resources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "amphotericin deoxycholate",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "antigen assays",
          "heading": false
        },
        {
          "term": "essential medicines",
          "heading": false
        },
        {
          "term": "induction regimen",
          "heading": false
        },
        {
          "term": "flucytosine",
          "heading": false
        }
      ],
      "extract": "Diagnosis Diagnosis is key to improving mortality from cryptococcal disease, and national programmes need to give priority to reliable access to rapid diagnostic cryptococcal antigen assays, preferably lateral flow assays for use in CSF and serum or plasma. In addition, health-care professionals need to have a low threshold for suspecting cryptococcal meningitis. Countries should develop plans to improve access to",
      "extractCut": true
    },
    {
      "id": "sec-031-5-research-needs",
      "number": "5",
      "title": "\u0007\u0007RESEARCH NEEDS",
      "level": 1,
      "pageStart": 38,
      "pageEnd": 39,
      "labelStart": "22",
      "labelEnd": "23",
      "words": 346,
      "summary": {
        "text": "Lists research needs, such as screening at CD4 counts of 100–200, using blood antigen titres to predict meningitis, managing relapse and integrating screening into advanced HIV care packages.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "antigen screening",
          "heading": false
        },
        {
          "term": "lumbar puncture",
          "heading": false
        },
        {
          "term": "research",
          "heading": true
        },
        {
          "term": "further research",
          "heading": false
        },
        {
          "term": "tertiary care",
          "heading": false
        },
        {
          "term": "amphotericin",
          "heading": false
        },
        {
          "term": "titres",
          "heading": false
        }
      ],
      "extract": "Further research is needed to assess the value of cryptococcal antigen screening at CD4 cell count thresholds between 100 and 200 cells/mm3, which has been suggested to save costs if carried out in inpatient settings. High cryptococcal antigen titres (>160) in blood have been found to predict subclinical meningitis. It has been suggested that blood titres could be used to predict meningitis in settings in which",
      "extractCut": true
    },
    {
      "id": "sec-032-6-updating-and-dissemination",
      "number": "6",
      "title": "UPDATING AND DISSEMINATION",
      "level": 1,
      "pageStart": 39,
      "pageEnd": 40,
      "labelStart": "23",
      "labelEnd": "24",
      "words": 223,
      "summary": {
        "text": "Describes how the guidelines will be disseminated, incorporated into consolidated HIV guidelines, adapted by countries and monitored through a WHO policy database.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dissemination",
          "heading": true
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "implementing partners",
          "heading": false
        },
        {
          "term": "adaptation",
          "heading": false
        },
        {
          "term": "updates",
          "heading": false
        },
        {
          "term": "country",
          "heading": false
        },
        {
          "term": "updated",
          "heading": false
        }
      ],
      "extract": "These guidelines will be launched as a web-based product for dissemination and will be supported by peer-reviewed publications of the systematic review and other evidence on which these recommendations are based. These guidelines will also be incorporated into the periodic updates of the WHO consolidated guidelines on HIV (75). The consolidated guidelines on HIV will be updated in full or in part based on regular",
      "extractCut": true
    },
    {
      "id": "sec-033-references",
      "number": null,
      "title": "References",
      "level": 1,
      "pageStart": 40,
      "pageEnd": 45,
      "labelStart": "24",
      "labelEnd": "29",
      "words": 2515,
      "summary": {
        "text": "The reference list for the cryptococcal disease guidelines, citing WHO guidance and studies on HIV-associated cryptococcal meningitis, followed by a table mapping recommendations to the evidence reviews.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "hiv-associated cryptococcal",
          "heading": false
        },
        {
          "term": "cryptococcal antigenemia",
          "heading": false
        },
        {
          "term": "cryptococcal meningoencephalitis",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "clin infect",
          "heading": false
        }
      ],
      "extract": "1. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/255884, accessed 9 March 2022). 2. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873–81. 3.",
      "extractCut": true
    },
    {
      "id": "sec-034-annex-1-process-for-developing-the-guidelines",
      "number": null,
      "title": "ANNEX 1. Process for developing the guidelines",
      "level": 1,
      "pageStart": 45,
      "pageEnd": 48,
      "labelStart": "29",
      "labelEnd": "32",
      "words": 869,
      "summary": {
        "text": "Annex 1 of the WHO cryptococcal disease guidelines outlines how they were developed, from the 2011 rapid advice and 2018 guidelines to a February 2022 Guideline Development Group meeting prompted by new evidence on induction therapy. It explains the use of GRADE to rate evidence certainty and set recommendation strength, and how evidence was summarized and presented. It also describes how declarations of interest from the Guideline Development Group and External Review Group were reviewed and managed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "managing cryptococcal",
          "heading": false
        },
        {
          "term": "guideline development",
          "heading": false
        },
        {
          "term": "group meeting",
          "heading": false
        },
        {
          "term": "group members",
          "heading": false
        },
        {
          "term": "external review",
          "heading": false
        },
        {
          "term": "guideline steering",
          "heading": false
        }
      ],
      "extract": "THE GUIDELINES WHO first published a rapid advice document on the diagnosis, prevention and management of cryptococcal disease in December 2011. In 2018, WHO published guidelines in response to new evidence relating to preventing, screening and treating cryptococcal disease. In 2021, new evidence on induction therapy was published that triggered a review of the evidence and a WHO guideline development process. A",
      "extractCut": true
    },
    {
      "id": "sec-035-references",
      "number": null,
      "title": "References",
      "level": 1,
      "pageStart": 48,
      "pageEnd": 49,
      "labelStart": "32",
      "labelEnd": "33",
      "words": 92,
      "summary": {
        "text": "A short reference list citing the trial of single-dose liposomal amphotericin B for cryptococcal meningitis, a related qualitative study protocol and an MSF report on access to liposomal amphotericin B.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "lawrence",
          "heading": false
        }
      ],
      "extract": "1. Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med 2022. 386(12):1109-1120. 2. Lawrence DS, Tsholo K, Ssali A, Mupambireyi Z, Hoddinott G, Nyirenda D et al. The Lived Experience Of Participants in an African RandomiseD trial (LEOPARD): protocol for an in-depth qualitative study within a multisite",
      "extractCut": true
    },
    {
      "id": "sec-036-web-annex-1-declarations-of-interest-for-the-gui",
      "number": null,
      "title": "Web Annex 1. Declarations of interest for the Guideline Development Group and External Peer Review Group",
      "level": 1,
      "pageStart": 49,
      "pageEnd": 53,
      "labelStart": "33",
      "labelEnd": "37",
      "words": 992,
      "summary": {
        "text": "Web Annex 1 tabulates declarations of interest for the 15 Guideline Development Group members, with their sex and regional breakdown, and records full participation for those listed. The page ends with the title and authors of Web Annex B, a systematic review and GRADE profile on treatment of HIV-associated cryptococcal meningitis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "external peer",
          "heading": true
        },
        {
          "term": "full participation",
          "heading": false
        },
        {
          "term": "peer review",
          "heading": true
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "review group",
          "heading": true
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "managing cryptococcal",
          "heading": false
        }
      ],
      "extract": "THE GUIDELINE DEVELOPMENT GROUP AND EXTERNAL PEER REVIEW GROUP Guideline Development Group members (n = 15) Sex Percentage Male 53% Female 47% Region Percentage African Region 47% Region of the Americas 27% European Region 6% Eastern Mediterranean Region 6% South-East Asia Region 6% Western Pacific Region 6% Name 1. Employment and consulting 2. Research support 3. Investment interests 4. Intellectual property 5.",
      "extractCut": true
    },
    {
      "id": "sec-037-abstract",
      "number": null,
      "title": "Abstract",
      "level": 2,
      "pageStart": 53,
      "pageEnd": 54,
      "labelStart": "37",
      "labelEnd": "38",
      "words": 261,
      "summary": {
        "text": "The abstract of a systematic review on induction therapy for HIV-associated cryptococcal meningitis, which found one trial of 844 people comparing a single high dose of liposomal amphotericin B plus flucytosine and fluconazole with seven days of amphotericin deoxycholate. It reports that the single-dose regimen was non-inferior for 10-week mortality and caused fewer severe adverse events.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "hiv-associated cryptococcal",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "induction therapy",
          "heading": false
        },
        {
          "term": "week mortality",
          "heading": false
        },
        {
          "term": "percentage points",
          "heading": false
        },
        {
          "term": "flucytosine",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        }
      ],
      "extract": "Objective: The purpose of this systematic review is to provide updated evidence on the preferred induction therapy for treating people with HIV-associated cryptococcal meningitis, considering the most recent evidence available, to inform the need for updates to WHO guidelines. Design: Systematic review. Methods: We searched Medline via PubMed, EMBASE, the Cochrane Library and ClinicalTrials. gov for published or",
      "extractCut": true
    },
    {
      "id": "sec-038-background",
      "number": null,
      "title": "Background",
      "level": 2,
      "pageStart": 54,
      "pageEnd": 54,
      "labelStart": "38",
      "labelEnd": "38",
      "words": 227,
      "summary": {
        "text": "Gives the background to the review, noting that cryptococcal meningitis is a leading cause of HIV deaths and that even the 2018 WHO-recommended regimen leaves high mortality and toxicity. It cites a trial in five African countries showing a single high dose of liposomal amphotericin B with two oral antifungals to be as effective, which prompted this update.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "induction therapy",
          "heading": false
        },
        {
          "term": "resource-limited settings",
          "heading": false
        },
        {
          "term": "clinical trials",
          "heading": false
        },
        {
          "term": "deoxycholate",
          "heading": false
        },
        {
          "term": "amphotericin",
          "heading": false
        },
        {
          "term": "flucytosine",
          "heading": false
        }
      ],
      "extract": "Cryptococcal meningitis is a leading cause of HIV-related mortality globally (1). A systematic review and network meta-analysis published in 2018 (2) provided evidence that, in resource-limited settings, one-week intravenous amphotericin B deoxycholate and oral flucytosine induction therapy was superior to other regimens that had been evaluated in clinical trials, and this formed the basis for guidelines published",
      "extractCut": true
    },
    {
      "id": "sec-039-methods",
      "number": null,
      "title": "Methods",
      "level": 2,
      "pageStart": 54,
      "pageEnd": 56,
      "labelStart": "38",
      "labelEnd": "40",
      "words": 614,
      "summary": {
        "text": "Describes the review methods, including eligibility of randomized trials comparing new induction regimens with WHO-recommended ones in people with a first episode of HIV-associated cryptococcal meningitis. It lists outcomes such as 2- and 10-week mortality, fungal clearance and serious laboratory adverse events, and explains the statistical analysis and use of GRADE for certainty.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "fungicidal activity",
          "heading": false
        },
        {
          "term": "conference abstracts",
          "heading": false
        },
        {
          "term": "eligibility criteria",
          "heading": false
        },
        {
          "term": "controlled trials",
          "heading": false
        },
        {
          "term": "cerebrospinal fluid",
          "heading": false
        },
        {
          "term": "search strategy",
          "heading": false
        },
        {
          "term": "clinical trials",
          "heading": false
        }
      ],
      "extract": "Eligibility criteria We included randomized controlled trials among people living with HIV with a first episode of cryptococcal meningitis evaluating induction regimens for treating people with cryptococcal meningitis not currently recommended by WHO guidelines. The standard-of-care arm had to include an induction regimen recommended by the WHO guidelines, either one week of amphotericin deoxycholate with",
      "extractCut": true
    },
    {
      "id": "sec-040-results",
      "number": null,
      "title": "Results",
      "level": 2,
      "pageStart": 56,
      "pageEnd": 57,
      "labelStart": "40",
      "labelEnd": "41",
      "words": 558,
      "summary": {
        "text": "Reports the study selection, in which one trial of 844 adults in Botswana, Malawi, South Africa, Uganda and Zimbabwe met the criteria, and describes its non-inferiority design. It summarizes the risk of bias and GRADE assessments, rating certainty low for mortality and fungal clearance and moderate for severe adverse events.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "fungicidal activity",
          "heading": false
        },
        {
          "term": "prespecified non-inferiority",
          "heading": false
        },
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "intervention arm",
          "heading": false
        },
        {
          "term": "control arm",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "log cfu",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        }
      ],
      "extract": "Study selection We identified 301 publications through database searches and one additional publication in press arising from an abstract from other sources (Fig. 1). After de-duplication, 276 records were available for reviewing titles and abstracts. Of these 276 records, 267 were excluded since they were not randomized clinical trials involving humans with results available. Nine records were available for full",
      "extractCut": true
    },
    {
      "id": "sec-041-discussion",
      "number": null,
      "title": "Discussion",
      "level": 2,
      "pageStart": 57,
      "pageEnd": 57,
      "labelStart": "41",
      "labelEnd": "41",
      "words": 334,
      "summary": {
        "text": "Discusses the findings, concluding that single high-dose liposomal amphotericin B with flucytosine and fluconazole was non-inferior to standard induction therapy with fewer adverse events. It notes the limitation of relying on one trial and differences between trial and routine settings, and states that WHO issued updated guidelines in March 2022 recommending the regimen, calling for wider access to the drugs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "single-dose liposomal",
          "heading": false
        },
        {
          "term": "hiv-associated cryptococcal",
          "heading": false
        },
        {
          "term": "induction therapy",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "flucytosine",
          "heading": false
        },
        {
          "term": "fewer adverse",
          "heading": false
        },
        {
          "term": "adverse events",
          "heading": false
        }
      ],
      "extract": "This updated review identified one study of 844 participants comparing a novel induction strategy for treating people with a first episode of HIV-associated cryptococcal meningitis. In the single study included in this systematic review, single high-dose (10 mg/kg) liposomal amphotericin B with flucytosine and fluconazole was non-inferior to the WHO-recommended standard-of-care induction therapy for HIV-associated",
      "extractCut": true
    },
    {
      "id": "sec-042-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 2,
      "pageStart": 57,
      "pageEnd": 57,
      "labelStart": "41",
      "labelEnd": "41",
      "words": 41,
      "summary": {
        "text": "An acknowledgement of US National Institute of Allergy and Infectious Diseases funding for one author, with a disclaimer about CDC views.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "allergy",
          "heading": false
        },
        {
          "term": "official",
          "heading": false
        },
        {
          "term": "centers",
          "heading": false
        }
      ],
      "extract": "RR is supported by the National Institute of Allergy and Infectious Diseases (K23AI138851, R01AI162181). The content is solely the responsibility of the authors and does not necessarily represent the official views of the United States Centers for Disease Control and Prevention.",
      "extractCut": false
    },
    {
      "id": "sec-043-fig-a1-study-selection",
      "number": null,
      "title": "Fig. A1. Study selection",
      "level": 2,
      "pageStart": 57,
      "pageEnd": 58,
      "labelStart": "41",
      "labelEnd": "42",
      "words": 75,
      "summary": {
        "text": "A flow diagram of study selection for the cryptococcal meningitis review, showing how 302 records were narrowed to one included randomized trial.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "rct",
          "heading": false
        },
        {
          "term": "non-hiv",
          "heading": false
        }
      ],
      "extract": "301 databases + 1 additional source 276 after de- duplication 267 excluded: not RCT, no results, animal studies 8 excluded from full-text review 4 non-flucytosine comparator arm 3 previously reviewed 1 non-HIV cryptococcal meningitis 8 published RCTs + 1 unpublished 1 RCT Web Annex B. Systematic review and GRADE evidence profile on treatment strategies for HIV-associated cryptococcal meningitis 42 Guidelines for",
      "extractCut": true
    },
    {
      "id": "sec-044-supplemental-fig-1-risk-of-bias-summary",
      "number": null,
      "title": "Supplemental Fig. 1. Risk of bias summary",
      "level": 2,
      "pageStart": 58,
      "pageEnd": 58,
      "labelStart": "42",
      "labelEnd": "42",
      "words": 42,
      "summary": {
        "text": "A risk of bias summary for the single included trial (Jarvis 2022), showing low risk in most domains but not for blinding.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "bias",
          "heading": true
        },
        {
          "term": "selection bias",
          "heading": false
        },
        {
          "term": "blinding",
          "heading": false
        }
      ],
      "extract": "Random sequence generation (selection bias) Allocation concealment (selection bias) Blinding of participants and personnel (performance bias) Blinding of outcome assessment (detection bias) Incomplete outcome data (attrition bias) Selective reporting (reporting bias) Other bias Jarvis 2022 + + – – + + +",
      "extractCut": false
    },
    {
      "id": "sec-045-appendix-search-strategy-utility-and-impact-revi",
      "number": null,
      "title": "Appendix. Search strategy: utility and impact review",
      "level": 2,
      "pageStart": 58,
      "pageEnd": 59,
      "labelStart": "42",
      "labelEnd": "43",
      "words": 143,
      "summary": {
        "text": "Gives the PubMed search strategy for the review, combining terms for HIV, cryptococcal meningitis and antifungal or other relevant drugs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tiab",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "immunodeficiency syndrome",
          "heading": false
        },
        {
          "term": "acquired immunodeficiency",
          "heading": false
        },
        {
          "term": "deficiency virus",
          "heading": false
        },
        {
          "term": "search",
          "heading": true
        },
        {
          "term": "human immunodeficiency",
          "heading": false
        }
      ],
      "extract": "The following search terms were used: 1. Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab]OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immunodeficiency virus[tiab] OR human immune- deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency",
      "extractCut": true
    },
    {
      "id": "sec-046-grade-evidence-profile-on-updated-systematic-rev",
      "number": null,
      "title": "GRADE evidence profile on updated systematic review of HIV-associated cryptococcal meningitis treatment strategies",
      "level": 2,
      "pageStart": 59,
      "pageEnd": 60,
      "labelStart": "43",
      "labelEnd": "44",
      "words": 197,
      "summary": {
        "text": "The GRADE evidence profile table for the single trial, summarizing 10-week mortality, early fungicidal activity and severe adverse events with relative and absolute effects and certainty ratings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "seriousa",
          "heading": false
        },
        {
          "term": "randomized trial",
          "heading": false
        },
        {
          "term": "serious",
          "heading": false
        },
        {
          "term": "seriousb",
          "heading": false
        },
        {
          "term": "fewer",
          "heading": false
        },
        {
          "term": "single study",
          "heading": false
        }
      ],
      "extract": "treatment strategies Certainty assessment Summary of findings Number of studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations Number of patients in intervention Number of patients in control Relative effect (95% CI) Absolute effect (95% CI) Certainty Importance 10-week mortality 1 Randomized trial Not serious Seriousa Not serious Seriousb None 101/407 (24.8%) 117/407 (28.7%)",
      "extractCut": true
    },
    {
      "id": "sec-047-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 60,
      "pageEnd": 61,
      "labelStart": "44",
      "labelEnd": "45",
      "words": 284,
      "summary": {
        "text": "The reference list for the systematic review, citing studies on the burden and treatment of HIV-associated cryptococcal meningitis, WHO guidance and methods resources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cryptococcal meningitis",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "jarvis",
          "heading": false
        },
        {
          "term": "engl med",
          "heading": false
        },
        {
          "term": "lancet infect",
          "heading": false
        },
        {
          "term": "chiller",
          "heading": false
        },
        {
          "term": "tenforde",
          "heading": false
        }
      ],
      "extract": "1. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873–81. 2. Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I et al. Treatment for HIV- associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;(7):CD005647. 3. Diagnosis, prevention and",
      "extractCut": true
    },
    {
      "id": "sec-048-web-annex-3-evidence-to-decision-making-table",
      "number": null,
      "title": "Web Annex 3. Evidence-to-decision-making table",
      "level": 1,
      "pageStart": 61,
      "pageEnd": 61,
      "labelStart": "45",
      "labelEnd": "45",
      "words": 4,
      "summary": {
        "text": "A heading page for the evidence-to-decision-making table annex; the extracted heading reads Annex 4 although the block is titled Web Annex 3.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "ANNEX 4. EVIDENCE-TO-DECISION-MAKING TABLE",
      "extractCut": false
    },
    {
      "id": "sec-049-summary-of-judgements",
      "number": null,
      "title": "Summary of judgements",
      "level": 2,
      "pageStart": 61,
      "pageEnd": 61,
      "labelStart": "45",
      "labelEnd": "45",
      "words": 141,
      "summary": {
        "text": "Summarizes the evidence-to-decision judgements, such as large benefits, moderate certainty, likely cost-effectiveness and acceptability, leading to a strong recommendation for single high-dose liposomal amphotericin B as induction therapy for cryptococcal disease.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "favours intervention",
          "heading": false
        },
        {
          "term": "yes",
          "heading": false
        },
        {
          "term": "variability",
          "heading": false
        },
        {
          "term": "uncertainty",
          "heading": false
        }
      ],
      "extract": "Question Judgement 1. Is the problem a priority? Yes 2. How substantial are the benefits? Large 3. How substantial is the harm? Large to moderate 4. What is the overall certainty of evidence? Moderate 5. What is the balance between benefits and harm? Favours intervention 6. \u0007Is there important variability or uncertainty in patient preferences regarding the key outcomes? No important uncertainty or variability 7. How",
      "extractCut": true
    },
    {
      "id": "sec-050-detailed-evidence-to-decision-making-table",
      "number": null,
      "title": "Detailed evidence-to-decision-making table",
      "level": 2,
      "pageStart": 61,
      "pageEnd": 64,
      "labelStart": "45",
      "labelEnd": "48",
      "words": 909,
      "summary": {
        "text": "The detailed evidence-to-decision table for single high-dose liposomal amphotericin B, explaining judgements on certainty, balance of benefits and harms, and values and preferences drawn from qualitative data from trial sites. It also covers resource use, cost-effectiveness, acceptability, feasibility and equity, noting likely benefits for children and settings unable to give longer amphotericin courses. The page ends with the ISBN and WHO HIV department contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "liposomal amphotericin",
          "heading": false
        },
        {
          "term": "amphotericin deoxycholate",
          "heading": false
        },
        {
          "term": "amphotericin regimen",
          "heading": false
        },
        {
          "term": "single-dose liposomal",
          "heading": false
        },
        {
          "term": "high-dose liposomal",
          "heading": false
        },
        {
          "term": "conventional amphotericin",
          "heading": false
        },
        {
          "term": "deoxycholate treatment",
          "heading": false
        },
        {
          "term": "fewer intravenous",
          "heading": false
        }
      ],
      "extract": "Factor Explanation and evidence Judgement Certainty of evidence A systematic review found one randomized controlled trial, and the evidence was considered to be of moderate certainty. Moderate Balance of benefits versus harm The evidence indicated that the single high-dose liposomal amphotericin regimen was non-inferior in terms of 10-week mortality to the current WHO- recommended treatment of seven daily doses of",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 1,
        "items": [
          "GRADE evidence profile on updated systematic review of HIV-associated cryptococcal meningitis treatment strategies"
        ]
      },
      "found_not_listed": {
        "count": 2,
        "items": [
          "3.6 Treatment for localized non-meningeal disease and disseminated cryptococcal disease other than meningitis",
          "1 RCT"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "cryptococcal meningitis",
      "heading": true
    },
    {
      "term": "cryptococcal antigen",
      "heading": false
    },
    {
      "term": "cryptococcal disease",
      "heading": true
    },
    {
      "term": "hiv-associated cryptococcal",
      "heading": true
    },
    {
      "term": "managing cryptococcal",
      "heading": true
    },
    {
      "term": "among cryptococcal",
      "heading": false
    },
    {
      "term": "csf cryptococcal",
      "heading": false
    },
    {
      "term": "preventing cryptococcal",
      "heading": true
    },
    {
      "term": "liposomal amphotericin",
      "heading": false
    },
    {
      "term": "serum cryptococcal",
      "heading": false
    },
    {
      "term": "treating cryptococcal",
      "heading": true
    },
    {
      "term": "associated cryptococcal",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "A",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "B",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "xi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "xii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "xiii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "xiv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 18,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "4",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "5",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "6",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "7",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 24,
      "label": "8",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "10",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "12",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 31,
      "label": "15",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 32,
      "label": "16",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 33,
      "label": "17",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 34,
      "label": "18",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "19",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 36,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 37,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "22",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 39,
      "label": "23",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 40,
      "label": "24",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 41,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "26",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "28",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "29",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 46,
      "label": "30",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "32",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 49,
      "label": "33",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 50,
      "label": "34",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 51,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 52,
      "label": "36",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "37",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 54,
      "label": "38",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 55,
      "label": "39",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 56,
      "label": "40",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 57,
      "label": "41",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 58,
      "label": "42",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 59,
      "label": "43",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 60,
      "label": "44",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 61,
      "label": "45",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 62,
      "label": "46",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "47",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "48",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "A1",
      "title": "Study selection\b",
      "page": 6,
      "pageLabel": "iv",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "graphic"
      ]
    },
    {
      "kind": "box",
      "number": "1",
      "title": "Common symptoms and signs of raised intracranial pressure",
      "page": 33,
      "pageLabel": "17",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p064-1",
      "file": "images/img-p064-1.webp",
      "page": 64,
      "narratives": {
        "en": "An ISBN barcode for the publication, labelled 9789240052178.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب (ISBN) الخاص بالمنشور، يحمل الرقم 9789240052178.",
        "zh": "本出版物的国际标准书号（ISBN）条形码，标注为9789240052178。",
        "es": "Código de barras del ISBN de la publicación, con el número 9789240052178.",
        "fr": "Code-barres ISBN de la publication, portant le numéro 9789240052178.",
        "ru": "Штрихкод ISBN издания с номером 9789240052178."
      },
      "state": "draft"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 52,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 52,
      "note": "3 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 1
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p40); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 51,
      "note": "51 of 52 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-357088"
  }
}
